» Articles » PMID: 16631086

Comparative in Vitro and in Vivo Evaluation of Two 64Cu-labeled Bombesin Analogs in a Mouse Model of Human Prostate Adenocarcinoma

Overview
Journal Nucl Med Biol
Publisher Elsevier
Date 2006 Apr 25
PMID 16631086
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Bombesin (BBN), an analog of human gastrin-releasing peptide (GRP), binds to the GRP receptor (GRPR) with high affinity and specificity. Overexpression of GRPR has been discovered in mostly androgen-independent human prostate tissues and, thus, provides a potential target for prostate cancer diagnosis and therapy. We have previously demonstrated the feasibility of the positron emission tomography (PET) imaging using 64Cu-1,4,7,10-tetraazadodecane-N,N',N'',N'''-tetraacetic acid (DOTA)-[Lys3]BBN to detect GRPR-positive prostate cancer. In this study, we compared the receptor affinity, metabolic stability, tumor-targeting efficacy, and pharmacokinetics of a truncated BBN analog 64Cu-DOTA-Aca-BBN(7-14) with 64Cu-DOTA-[Lys3]BBN. Binding of each DOTA conjugate to GRPR on PC-3 and 22Rv1 prostate cancer cells was evaluated with competitive binding assay using 125I-[Tyr4]BBN as radioligand. In vivo pharmacokinetics was determined on male nude mice subcutaneously implanted with PC-3 cells. Dynamic microPET imaging was performed to evaluate the systemic distribution of the tracers. Metabolic stability of the tracers in blood, urine, tumor, liver and kidney was studied using high-performance liquid chromatography. The results showed that 125I-[Tyr4]BBN has a K(d) of 14.8+/-0.4 nM against PC-3 cells, and the receptor concentration on PC-3 cell surface is approximately 2.7+/-0.1 x 10(6) receptors per cell. The 50% inhibitory concentration value for DOTA-Aca-BBN(7-14) is 18.4 +/- 0.2 nM, and that for DOTA-[Lys3]BBN is 2.2 +/- 0.5 nM. DOTA-[Lys3]BBN shows a better tumor contrast and absolute tumor activity accumulation compared to DOTA-Aca-BBN(7-14). Studies on metabolic stability for both tracers on organ homogenates showed that 64Cu-DOTA-[Lys3]BBN is relatively stable. This study demonstrated that both tracers are suitable for targeted PET imaging to detect the expression of GRPR in prostate cancer, while 64Cu-DOTA-[Lys3]BBN may have a better potential for clinical translation.

Citing Articles

Advances of radiolabeled GRPR ligands for PET/CT imaging of cancers.

Yuze Ma , Gao F Cancer Imaging. 2024; 24(1):19.

PMID: 38279185 PMC: 10811881. DOI: 10.1186/s40644-024-00658-y.


Water-Soluble Chitosan Conjugated DOTA-Bombesin Peptide Capped Gold Nanoparticles as a Targeted Therapeutic Agent for Prostate Cancer.

Tangthong T, Piroonpan T, Thipe V, Khoobchandani M, Katti K, Katti K Nanotechnol Sci Appl. 2021; 14:69-89.

PMID: 33776426 PMC: 7987316. DOI: 10.2147/NSA.S301942.


Functional Hybrid Molecules for the Visualization of Cancer: PESIN-Homodimers Combined with Multimodal Molecular Imaging Probes for Positron Emission Tomography and Optical Imaging: Suited for Tracking of GRPR-Positive Malignant Tissue*.

Hubner R, Cheng X, Wangler B, Wangler C Chemistry. 2020; 26(69):16349-16356.

PMID: 32618007 PMC: 7756681. DOI: 10.1002/chem.202002386.


Radiolabeled bombesin derivatives for preclinical oncological imaging.

de Aguiar Ferreira C, Fuscaldi L, Townsend D, Rubello D, de Barros A Biomed Pharmacother. 2017; 87:58-72.

PMID: 28040598 PMC: 5331929. DOI: 10.1016/j.biopha.2016.12.083.


Synthesis and Biological Evaluation of an (18)Fluorine-Labeled COX Inhibitor--[(18)F]Fluorooctyl Fenbufen Amide--For Imaging of Brain Tumors.

Huang Y, Chang Y, Yeh C, Yu C Molecules. 2016; 21(3):387.

PMID: 27007363 PMC: 6273898. DOI: 10.3390/molecules21030387.